Results 11 to 20 of about 11,979 (257)

Advances in oncolytic virotherapy

open access: yesCommunications Medicine, 2022
Recent years have seen rapid advances in the preclinical development and clinical evaluation of oncolytic (cancer-lysing) virus-based therapies, and these are emerging as treatment modality for some cancers.
Stephen J. Russell   +3 more
doaj   +4 more sources

Oncolytic virotherapy as immunotherapy

open access: yesScience, 2021
Description Recognizing immune responses to oncolytic virotherapy opens the way for new combinations Oncolytic virus (OV) therapy is now something of a misnomer.
A. Melcher, K. Harrington, R. Vile
semanticscholar   +3 more sources

Oncolytic virotherapy

open access: yesAnnals of Hepatology, 2008
Current oncolytic virotherapy strategies are based in the accumulated understanding of the common molecular mechanisms displayed during cell transformation and viral infection, like cell cycle and apoptosis deregulations.
Daniel Cervantes-García;   +3 more
doaj   +4 more sources

Virotherapy combined with anti-PD-1 transiently reshapes the tumor immune environment and induces anti-tumor immunity in a preclinical PDAC model

open access: yesFrontiers in Immunology, 2023
IntroductionPancreatic ductal adenocarcinoma (PDAC) is largely refractory to cancer immunotherapy with PD-1 immune checkpoint blockade (ICB). Oncolytic virotherapy has been shown to synergize with ICB.
Rūta Veinalde   +22 more
doaj   +2 more sources

Strategies for Advanced Oncolytic Virotherapy: Current Technology Innovations and Clinical Approaches

open access: yesPharmaceutics, 2022
Oncolytic virotherapy is a type of nanomedicine with a dual antitumor mechanism. Viruses are engineered to selectively infect and lyse cancer cells directly, leading to the release of soluble antigens which induce systemic antitumor immunity ...
Qing Ji   +4 more
doaj   +2 more sources

The combination therapy of oncolytic virotherapy

open access: yesFrontiers in Pharmacology
Introduction: Compared to other cancer immunotherapies, oncolytic viruses possess several advantages, including high killing efficiency, excellent targeting capabilities, minimal adverse reactions, and multiple pathways for tumor destruction.
Yue Wang   +4 more
semanticscholar   +4 more sources

Oncolytic virotherapy: basic principles, recent advances and future directions

open access: yesSignal Transduction and Targeted Therapy, 2023
Oncolytic viruses (OVs) have attracted growing awareness in the twenty-first century, as they are generally considered to have direct oncolysis and cancer immune effects.
Danni Lin, Yinan Shen, T. Liang
semanticscholar   +1 more source

Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial

open access: yesNature Network Boston, 2023
Immune-mediated anti-tumoral responses, elicited by oncolytic viruses and augmented with checkpoint inhibition, may be an effective treatment approach for glioblastoma. Here in this multicenter phase 1/2 study we evaluated the combination of intratumoral
F. Nassiri   +38 more
semanticscholar   +1 more source

Oncolytic viruses-modulated immunogenic cell death, apoptosis and autophagy linking to virotherapy and cancer immune response

open access: yesFrontiers in Cellular and Infection Microbiology, 2023
Recent reports have revealed that oncolytic viruses (OVs) play a significant role in cancer therapy. The infection of OVs such as oncolytic vaccinia virus (OVV), vesicular stomatitis virus (VSV), parvovirus, mammalian reovirus (MRV), human adenovirus ...
Yi-Ying Wu   +4 more
semanticscholar   +1 more source

Oncolytic virotherapy [PDF]

open access: yesNature Biotechnology, 2012
Oncolytic virotherapy is an emerging treatment modality that uses replication-competent viruses to destroy cancers. Recent advances include preclinical proof of feasibility for a single-shot virotherapy cure, identification of drugs that accelerate intratumoral virus propagation, strategies to maximize the immunotherapeutic action of oncolytic viruses ...
Russell, Stephen J   +2 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy